Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 42Y93 | — |
Kinrix vaccine was administer to a 9 months male baby; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 9-month-old male patient who received DTPa-IPV (Kinrix) (batch number 42Y93, expiry date 05-JUN-2026) for prophylaxis. Concomitant products included Diphtheria vaccine toxoid, Pertussis vaccine acellular, Tetanus vaccine toxoid (Dtap) and Diphtheria vaccine toxoid, Pertussis vaccine acellular, Tetanus vaccine toxoid (IPV). On 11-MAR-2025, the patient received Kinrix. On 11-MAR-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Kinrix vaccine was administer to a 9 months male baby). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-APR-2025 The nurse reported that the patient received Kinrix vaccine and was administered to a 9 months old patient and with this last vaccine the patient had 3 Dtap and 3 IPV doses The Vaccine Administration Facility was the same as Primary Reporter. The patient received a dose of Kinrix at an inappropriate age, which led to inappropriate age at vaccine administration.
Dtap; IPV